Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Authors: Hedy L. Kindler, Silvia Novello, Alessandra Bearz, Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A. Burgers, Armando Santoro, S. Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P. van Meerbeeck, Anna K. Nowak, George R. Blumenschein, Jonathan Siegel, Linda Kasten, Karl Köchert, Annette O. Walter, Barrett H. Childs, Cem Elbi, Raffit Hassan, Dean A. Fennell - The Lancet 2022 cited by 68